What cases resistance to rilpivirine in antiretroviral therapy of HIV infection?

Updated: Apr 18, 2019
  • Author: R Chris Rathbun, PharmD, BCPS (AQ-ID), AAHIVP; Chief Editor: John Bartlett, MD  more...
  • Print


Rilpivirine has a lower genetic barrier to resistance than etravirine.  While cross resistance with first-generation NNRTIs does not occur with the K103N mutation, decreased susceptibility to rilpivirine is predicted from in vitro and clinical studies with any of the following mutations: K101E/P, E138K/A/G/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C, M230I/L. [33]   Patients with baseline plasma HIV RNA greater than 100,000 copies/mL are also more likely to develop NRTI resistance mutations when used in combination with rilpivirine than with efavirenz. [34]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!